SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration (the "FDA") informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA").
LEUVEN, Belgium, February 9/PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.
PARIS, Feb. 9 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc. (NASDAQ:CHTT) .
LAUSANNE, Switzerland, February 9/PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect.
LONDON, Feb. 9 /PRNewswire/ -- Biomarker analysis market has excellent growth potential. The 'omics' revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. Biomarkers have a multitude of applications such as early disease detection, identifying potential drug targets, predicting patient response to medication and accelerating clinical trials.
SILVER SPRING, Md., Feb. 9 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that it will release its fourth quarter and annual 2009 financial results before market open on Tuesday, February 16, 2010.
LOS ANGELES, Feb. 9 /PRNewswire/ -- BBK Worldwide, patient recruitment leader and clinical research and development consultancy, announces the opening of a West Coast office in Los Angeles. This expansion is a response to increasing demands from biotechnology/biopharmaceutical research sponsors for worldwide coverage to successfully meet recruitment deadlines. Building on the 2009 office opening of BBK Worldwide - Osaka in Japan, and adding to BBK's existing global alliance network and Boston, London, and Prague locations, the Los Angeles office creates an opportunity for BBK to better serve clients in the Pacific time zone.
CARMEL, Ind., Feb. 9 /PRNewswire/ -- The American Psychiatric Association (APA) has chosen CME Enterprise as the sole medical education partner to prepare and manage all industry-supported symposia (ISS) programming at its annual meeting in New Orleans, Louisiana, from May 22-26, 2010.
NASHVILLE, Tenn., Feb. 9 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, today announced the company is now offering PatientFinder, a healthcare analytics tool that assesses local markets for pharmaceutical company expansion opportunity by determining the number of insured patients in a territory who have a specific disease but are untreated.
CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.
BERKELEY, Calif., Feb 9, 2010 (GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody candidate, XOMA 052, in Type 2 diabetes patients.
09 February 2010, London, UK and Cambridge, MA: - Antisoma plc (LSE: ASM; USOTC: ATSMY) will be announcing its interim results for the six months ended 31 December 2009 on Thursday 18 February 2010.
NEW YORK, Feb. 9 /PRNewswire/ -- Intrasphere Technologies, a leading consulting and solutions firm that provides business-focused services and software solutions to Life Sciences organizations, announced today the launch of PharmaCM CTR Express for Clinical Trial Registration. PharmaCM CTR Express is a comprehensive clinical trial registration and results disclosure solution that is fully pre-configured for quick deployment. Offered as Software as a Service (SaaS), the solution is a fully validated application, hosted by Intrasphere and updated regularly to keep current with rapidly evolving trial disclosure requirements.
Nijmegen, the Netherlands, 8 February 2010 – Synthon is pleased to announce that Rudy Mareel has joined the company as CEO.
ESPOO, Finland, Feb. 9, 2010--Orion's net sales in 2009 totalled EUR 771.5 million (EUR 710.7 million in 2008), up by 8.5% on the previous year.
Basel, February 9, 2010 - Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibodies unit AbD Serotec will expand its sales organization in Düsseldorf to support growth in continental and eastern Europe as well as in Asia. Today's official opening ceremony was performed by Friedrich G. Conzen, major of Düsseldorf.
Leiden, the Netherlands (February 9, 2010) - Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced its financial results for the fourth quarter and full year of 2009, based on International Financial Reporting Standards (IFRS). These financial results are unaudited.
Rennes, France — February 9th, 2010 -- Biotrial is pleased to announce that it will be exhibiting at the 20th AGAH (Association for Applied Human Pharmacology) Annual Meeting in Hamburg, Germany and at the 9th Annual Phase I Clinical Trials in London, UK.
CHARLOTTE, N.C., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced several updates related to its Phase III registration program in neurogenic orthostatic hypotension (NOH), including the selection and preliminary approval by the FDA of Northera as the U.S. brand name for Droxidopa in this indication.
|
